Skip to main content
Clinical Trials/NCT02225964
NCT02225964CompletedNot Applicable

Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD

XuanwuH 21 site in 1 country200 target enrollmentStarted: January 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
the conversion of aMCI patients with APOEε4 to AD

Study Overview

Brief Summary

This study is to find out the imaging marker and the changing laws of the marker during the course of the disease. The final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of Alzheimer's disease.

Detailed Description

It is an urgent problem in the field of cognitive neuroscience to tell the conversion progression of amnestic mild cognitive impairment(aMCI) patients with Apolipoproteinε4(APOEε4) to Alzheimer's Disease(AD). Based on our preliminary work, we will study the special group of aMCI patients with APOEε4 with multi-modality magnetic resonance imaging (resting-state functional MRI, structural MRI and diffusion tensor imaging) longitudinally. Besides, we will also detect the APOE genotype of each sample and enlarge the sample size. According to situation of the conversion or non-conversion and differences in the conversion progression, we will analyze the data between the inter-groups and intra-groups, compare the imaging data of baseline and follow-up, find the prediction imaging marker of AD and optimize the reliability and validity.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Complaint about memory loss and confirmed by an informant
  • Cognitive impairment in single or multiple domains, adjusted for age and education
  • Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities
  • A Clinical Dementia Rating (CDR) score is 0.5
  • Failure to meet the criteria for dementia
  • Carrying susceptible gene APOEε4
  • Must be able to accept examination of MRI, sight and hearing allow to complete test

Exclusion Criteria

  • Other diseases that cause cognitive impairment,such as thyroid disease,stroke and so on
  • people who have severe visual and hearing impairment

Outcomes

Primary Outcomes

the conversion of aMCI patients with APOEε4 to AD

Time Frame: one year

According to situation of the conversion or non-conversion and differences in the conversion progression, we will analyze the data between the inter-groups and intra-groups, compare the imaging data of baseline and follow-up, find the prediction imaging marker of AD and optimize the reliability and validity.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
XuanwuH 2
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

XuanwuH 2

Chief physician

Xuanwu Hospital, Beijing

Study Sites (1)

Loading locations...

Similar Trials